Chronic Lower Back Pain Pipeline Insight
DelveInsight’s, “Chronic Lower Back Pain -Pipeline Insights, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Lower Back Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Chronic Lower Back Pain Understanding
Chronic Lower Back Pain: Overview
Chronic back pain is defined as pain that continues for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain has been treated. About 20 percent of people affected by acute low back pain develop chronic low back pain with persistent symptoms at one year. Even if pain persists, it does not always mean there is a medically serious underlying cause or one that can be easily identified and treated. The lower back—where most back pain occurs—includes the five vertebrae (referred to as L1-L5) in the lumbar region, which supports much of the weight of the upper body. The spaces between the vertebrae are maintained by round, rubbery pads called intervertebral discs that act like shock absorbers throughout the spinal column to cushion the bones as the body moves. Bands of tissue known as ligaments hold the vertebrae in place, and tendons attach the muscles to the spinal column. Thirty-one pairs of nerves are rooted to the spinal cord and they control body movements and transmit signals from the body to the brain. Other regions of vertebrate are cervical (in the neck), thoracic (upper back), and sacral and coccygeal (below the lumbar area) segments.
Symptoms range from a dull ache to a stabbing or shooting sensation. The pain may make it hard to move or stand up straight. Pain that lasts more than three months is considered chronic. Other warning signs include a loss of bowel or bladder control, numbness in the groin area, leg weakness, fever, and pain when coughing or urinating.
Imaging tests such as X-rays, CT scans, ultrasounds, and MRIs may be necessary so the doctor can check for: bone problems, disc problems, problems with the ligaments and tendons in back.
Chronic back pain is most often treated with a stepped care approach, moving from simple low-cost treatments to more aggressive approaches. Specific treatments may depend on the identified cause of the back pain. Medications may include:
- Analgesics and NSAIDS
- Opioid drugs
Other treatments include Surgery, Vertebroplasty and kyphoplasty, Spinal laminectomy, Discectomy and microdiscectomy, Foraminotomy, Nucleoplasty, Radiofrequency denervation, Spinal fusion.
Chronic Lower Back Pain Emerging Drugs Chapters
This segment of the Chronic Lower Back Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Lower Back Pain Emerging Drugs
- PP353: Persica Pharmaceuticals Ltd.
With PP353, Persica’s objective is to replace the 100-day high-dose oral antibiotics course to treat CLBP, which have been shown to be effective in the clinical trials with an injectable antibiotic formulation that will achieve high local concentration and adequate duration of exposure in the spine to effect the sterilisation of the infected disc.
- Rexlemestrocel-L: Mesoblast Ltd.
Rexlemestrocel-L (Revascor; Mesoblast) is an investigational allogeneic mesenchymal precursor cell therapy under development for injection into the heart muscle in patients with moderate to advanced or end-stage chronic HF.
Further product details are provided in the report……..
Chronic Lower Back Pain: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Lower Back Pain drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Lower Back Pain
There are approx. 5+ key companies which are developing the therapies for Chronic Lower Back Pain. The companies which have their Chronic Lower Back Pain drug candidates in the most advanced stage, i.e. phase III include, Mesoblast, Persica Pharmaceuticals Ltd., AnGes, Inc. and others.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Chronic Lower Back Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as:
- Small molecules
- Stem-cell therapies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Lower Back Pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Lower Back Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Lower Back Pain drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Lower Back Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Lower Back Pain.
- June 2020: New therapy reduces chronic low back pain in large international study
- A new study has found that tanezumab, a monoclonal antibody that inhibits nerve activity, provides relief in patients with chronic low back pain, one of the leading reasons why people seek medical care and the number one cause of disability worldwide. Researchers are increasingly finding that certain proteins circulating in the bloodstream heighten the sensitivity of cells in the nervous system to pain. One of these proteins, called nerve growth factor (NGF), may explain why some individuals experience more intense and chronic back pain. Tanezumab is an NGF inhibitor.
- June 2020: Relievant Announces Publication of 5-Year Data Demonstrating Long Term Clinical Benefits of the Intracept Procedure in Chronic Low Back Pain Patients
Relievant Medsystems announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years for patients treated with the Intracept procedure. The recently published long-term studyi is a single-arm, open-label, prospective follow-up of 100 US patients (85% retention) who were successfully treated with basivertebral nerve ablation in the SMART randomized study. Mean patient follow-up was 6.4 years post-procedure (range: 5.4 - 7.8 years). The study evaluated functional impact using the Oswestry Disability Index (ODI), low back pain scores using a Visual Analog Scale (VAS), pain interventions post-BVN ablation, and patient satisfaction.
Chronic Lower Back Pain Report Insights
- Chronic Lower Back Pain Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Chronic Lower Back Pain Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Lower Back Pain drugs?
- How many Chronic Lower Back Pain drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Lower Back Pain?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Lower Back Pain therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Lower Back Pain and their status?
- What are the key designations that have been granted to the emerging drugs?
- Persica Pharmaceuticals Ltd.
- Micron Research Ltd.
- Mesoblast, Ltd.
- Allogenic BM-MSCs Injection
- AnGes, Inc.
- Allogenic BM-MSCs Injection